Follicular lymphoma in the modern era: survival, treatment outcomes, and identification of high-risk subgroups.

Blood Cancer Journal
Connie L BatleviAnas Younes

Abstract

Patients with follicular lymphoma (FL) frequently require multiple treatments during their disease course; however, survival based on lines of treatment remains poorly described in the post-rituximab era. Also, the Follicular Lymphoma International Prognostic Index (FLIPI) score was developed to predict survival at diagnosis, yet it remains unknown whether increase in FLIPI score following an initial observation period is associated with less-favorable outcomes. To address these knowledge gaps, we retrospectively studied 1088 patients with FL grade 1-3A managed between 1998 and 2009 at our institution. Median overall survival (OS) and progression-free survival (PFS) after first-line treatment were not reached and 4.73 years, respectively. Following successive lines of treatment, years of median OS and PFS were, respectively: after second-line, 11.7 and 1.5; third-line, 8.8 and 1.1; fourth-line, 5.3 and 0.9; fifth-line, 3.1 and 0.6; sixth-line, 1.9 and 0.5. In initially observed, subsequently treated patients, FLIPI score increase after observation was associated with inferior survival following first-line treatment. The reduced survival we observed after second-line and later therapy supports the development of new treatments f...Continue Reading

References

Jan 1, 1979·Annals of Internal Medicine·C S Portlock, S A Rosenberg
Oct 1, 1986·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·C J GallagherT A Lister
Dec 6, 1984·The New England Journal of Medicine·S J Horning, S A Rosenberg
Jan 1, 1995·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·P W JohnsonT A Lister
Apr 1, 1997·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Y BastionB Coiffier
May 6, 2004·Blood·Philippe Solal-CélignyEmili Montserrat
Sep 10, 2005·Blood·Lindsay M MortonMartha S Linet
May 9, 2007·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Silvia MontotoT Andrew Lister
Oct 8, 2008·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Abdulwahab J Al-TourahJoseph M Connors
Jun 25, 2009·Annals of Oncology : Official Journal of the European Society for Medical Oncology·S A M van de SchansD J van Spronsen
Aug 5, 2009·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Massimo FedericoPhilippe Solal-Céligny
Jan 7, 2015·CA: a Cancer Journal for Clinicians·Rebecca L SiegelAhmedin Jemal
Jul 1, 2015·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Carla CasuloJonathan W Friedberg
Jan 24, 2016·Annals of Oncology : Official Journal of the European Society for Medical Oncology·C Y CheahN H Fowler
Jun 15, 2016·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Clémentine SarkozyHervé Tilly
Oct 21, 2016·American Journal of Hematology·Matthew J MaurerBrian K Link
May 12, 2017·PloS One·Mariano ProvencioUNKNOWN GOTEL (Spanish Lymphoma Oncology Group)
Oct 5, 2017·The New England Journal of Medicine·Robert MarcusWolfgang Hiddemann
Nov 3, 2017·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Stefano LuminariMassimo Federico
Sep 6, 2018·The New England Journal of Medicine·Franck MorschhauserUNKNOWN RELEVANCE Trial Investigators
Jul 25, 2019·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Emmanuel BachyGilles Salles

❮ Previous
Next ❯

Citations

Jan 8, 2021·Journal of Hematology & Oncology·Melissa LumishErel Joffe
Feb 4, 2021·Cancer Management and Research·Ayushi F Chauhan, Bruce D Cheson
Feb 23, 2021·Drugs·Michael Northend, William Townsend
Feb 27, 2021·Deutsches Ärzteblatt International·Anna ZoellnerWolfgang Hiddemann
Jul 18, 2021·PharmacoEconomics·Caitlin EichtenRichard T Maziarz

❮ Previous
Next ❯

Methods Mentioned

BETA
biopsy

Software Mentioned

LymphoCare
PRIMA

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.